{"id":514331,"date":"2021-07-19T07:03:52","date_gmt":"2021-07-19T11:03:52","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-to-present-ath-1017-phase-1-translational-data-at-the-alzheimers-association-international-conference-2021-aaic\/"},"modified":"2021-07-19T07:03:52","modified_gmt":"2021-07-19T11:03:52","slug":"athira-pharma-to-present-ath-1017-phase-1-translational-data-at-the-alzheimers-association-international-conference-2021-aaic","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-to-present-ath-1017-phase-1-translational-data-at-the-alzheimers-association-international-conference-2021-aaic\/","title":{"rendered":"Athira Pharma to Present ATH-1017 Phase 1 Translational Data at the Alzheimer\u2019s Association International Conference 2021 (AAIC)"},"content":{"rendered":"
\n

BOTHELL, Wash., July 19, 2021 (GLOBE NEWSWIRE) — Athira Pharma, Inc.<\/a> (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that it will present clinical electroencephalogram (EEG) data, including in Alzheimer\u2019s patients, from the Phase 1 a\/b trial of its lead development candidate, ATH-1017, at the upcoming Alzheimer\u2019s Association International Conference 2021 (AAIC). AAIC will be held July 26-30, 2021, virtually and in Denver.<\/p>\n

\n Poster Presentation Details<\/strong>:<\/p>\n

\n Title:<\/strong> Quantitative EEG as a translational measure for the assessment of ATH-1017 neurophysiological changes in mild-to-moderate Alzheimer\u2019s disease<\/p>\n

\n Poster Number: <\/strong>56531<\/p>\n

\n Presenter:<\/strong> Xue Hua, Ph.D., Vice President of Clinical Development, Research, Athira Pharma<\/p>\n

\n Authors:<\/strong> Xue Hua1<\/sup>, Kevin Church1<\/sup>, William Walker1<\/sup>, Phillippe L\u2019Hostis2<\/sup>, Larry Ereshefsky3,4<\/sup>, Hans J. Moebius1<\/sup><\/p>\n

\n 1<\/sup>Athira Pharma, Inc.; 2<\/sup>Biotrial Core Lab, Drug Evaluation and Pharmacology Research; 3<\/sup>Follow the Molecule: CNS Consulting LLC, CA, 4<\/sup>Retired Professor and Program Head, University of Texas Health Sciences<\/p>\n

The poster presentation will be available beginning at 8 a.m. MT \/ 10 a.m. ET Monday, July 26, on the AAIC meeting platform. The poster will also be available on the Events & Presentations page of the Athira website https:\/\/investors.athira.com\/news-and-events\/events-and-presentations<\/a>.<\/p>\n

\n About ATH-1017 <\/strong>
\n
ATH-1017 is a small molecule therapeutic specifically designed to enhance the activity of Hepatocyte Growth Factor (HGF) and its receptor, MET, which are expressed in normal central nervous system function, in order to impact neurodegeneration and regenerate brain tissue. In addition to Alzheimer\u2019s disease, ATH-1017 is designed to address the broader dementia population, including Parkinson\u2019s disease dementia.<\/p>\n

\n About Athira Pharma, Inc.<\/strong>
\n
Athira, headquartered in the Seattle area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. We aim to provide rapid cognitive improvement and alter the course of neurological diseases with our novel mechanism of action. Athira is currently advancing its lead therapeutic candidate, ATH-1017, a novel small molecule for Alzheimer\u2019s and Parkinson\u2019s dementia. For more information, visit\u00a0www.athira.com<\/a>. You can also follow Athira on\u00a0Facebook<\/a>,\u00a0LinkedIn<\/a>\u00a0and\u00a0@athirapharma on\u00a0Twitter<\/a>\u00a0and\u00a0Instagram<\/a>.<\/p>\n

\n Forward-Looking Statements<\/strong>
\n
This release contains \u201cforward-looking statements\u201d within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include statements regarding ATH-1017 as a potential treatment for Alzheimer\u2019s disease and other dementias; Athira\u2019s platform technology and potential therapies; expectations regarding the potential efficacy and commercial potential of Athira\u2019s product candidates; the anticipated presentation of data; and Athira\u2019s ability to advance its product candidates into later stages of development. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words and phrases such as \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201cbelieve,\u201d \u201cintend,\u201d \u201cpursue,\u201d \u201ccontinue,\u201d and other similar expressions, among others. Any forward-looking statements are based on management\u2019s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the preliminary data for Athira\u2019s ATH-1017 product candidate from the Phase 1a\/b trials will not continue or persist; cessation or delay of any of the ongoing clinical trials and\/or Athira\u2019s development of ATH-1017 may occur; future potential regulatory milestones of ATH-1017, including those related to current and planned clinical studies may be insufficient to support regulatory submissions or approval; the impact of the COVID-19 pandemic on Athira\u2019s business, research and clinical development plans and timelines and results of operations, including impact on Athira\u2019s clinical trial sites and contractors who act for or on Athira\u2019s behalf, may be more severe and more prolonged than currently anticipated; clinical trials may not demonstrate safety and efficacy of any of Athira\u2019s product candidates; Athira\u2019s research and development efforts and its ability to advance product candidates into later stages of development may fail; any one or more of Athira\u2019s product candidates may not be successfully developed, approved or commercialized; while P300 latency is a functional measure that is highly correlated with cognition, Athira may not successfully establish a connection between these P300 latency results and improved cognition; adverse conditions in the general domestic and global economic markets; regulatory uncertainty as a result of the new U.S. administration; regulatory agencies may be delayed in reviewing, commenting on or approving any of Athira\u2019s clinical development plans as a result of the COVID-19 pandemic, which could further delay development timelines; the impact of competition; the impact of expanded product development and clinical activities on operating expenses; impact of new or changing laws and regulations; as well as the other risks detailed in Athira\u2019s filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof and Athira undertakes no obligation to update forward-looking statements. Athira may not actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements, and you should not place undue reliance on the forward-looking statements.<\/p>\n

\n Investor & Media Contact<\/strong>:
Julie Rathbun
Athira Pharma
Julie.rathbun@athira.com<\/a>
206-769-9219<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

BOTHELL, Wash., July 19, 2021 (GLOBE NEWSWIRE) — Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that it will present clinical electroencephalogram (EEG) data, including in Alzheimer\u2019s patients, from the Phase 1 a\/b trial of its lead development candidate, ATH-1017, at the upcoming Alzheimer\u2019s Association International Conference 2021 (AAIC). AAIC will be held July 26-30, 2021, virtually and in Denver. Poster Presentation Details: Title: Quantitative EEG as a translational measure for the assessment of ATH-1017 neurophysiological changes in mild-to-moderate Alzheimer\u2019s disease Poster Number: 56531 Presenter: Xue Hua, Ph.D., Vice President of Clinical Development, Research, Athira Pharma Authors: Xue Hua1, Kevin Church1, William Walker1, Phillippe … <\/p>\n

Continue reading “Athira Pharma to Present ATH-1017 Phase 1 Translational Data at the Alzheimer\u2019s Association International Conference 2021 (AAIC)”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-514331","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAthira Pharma to Present ATH-1017 Phase 1 Translational Data at the Alzheimer\u2019s Association International Conference 2021 (AAIC) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-to-present-ath-1017-phase-1-translational-data-at-the-alzheimers-association-international-conference-2021-aaic\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Athira Pharma to Present ATH-1017 Phase 1 Translational Data at the Alzheimer\u2019s Association International Conference 2021 (AAIC) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BOTHELL, Wash., July 19, 2021 (GLOBE NEWSWIRE) — Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that it will present clinical electroencephalogram (EEG) data, including in Alzheimer\u2019s patients, from the Phase 1 a\/b trial of its lead development candidate, ATH-1017, at the upcoming Alzheimer\u2019s Association International Conference 2021 (AAIC). AAIC will be held July 26-30, 2021, virtually and in Denver. Poster Presentation Details: Title: Quantitative EEG as a translational measure for the assessment of ATH-1017 neurophysiological changes in mild-to-moderate Alzheimer\u2019s disease Poster Number: 56531 Presenter: Xue Hua, Ph.D., Vice President of Clinical Development, Research, Athira Pharma Authors: Xue Hua1, Kevin Church1, William Walker1, Phillippe … Continue reading "Athira Pharma to Present ATH-1017 Phase 1 Translational Data at the Alzheimer\u2019s Association International Conference 2021 (AAIC)"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-to-present-ath-1017-phase-1-translational-data-at-the-alzheimers-association-international-conference-2021-aaic\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-19T11:03:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4MTk4MiM0MzAxNDc4IzIyMDE4OTE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-to-present-ath-1017-phase-1-translational-data-at-the-alzheimers-association-international-conference-2021-aaic\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-to-present-ath-1017-phase-1-translational-data-at-the-alzheimers-association-international-conference-2021-aaic\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Athira Pharma to Present ATH-1017 Phase 1 Translational Data at the Alzheimer\u2019s Association International Conference 2021 (AAIC)\",\"datePublished\":\"2021-07-19T11:03:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-to-present-ath-1017-phase-1-translational-data-at-the-alzheimers-association-international-conference-2021-aaic\\\/\"},\"wordCount\":901,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-to-present-ath-1017-phase-1-translational-data-at-the-alzheimers-association-international-conference-2021-aaic\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4MTk4MiM0MzAxNDc4IzIyMDE4OTE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-to-present-ath-1017-phase-1-translational-data-at-the-alzheimers-association-international-conference-2021-aaic\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-to-present-ath-1017-phase-1-translational-data-at-the-alzheimers-association-international-conference-2021-aaic\\\/\",\"name\":\"Athira Pharma to Present ATH-1017 Phase 1 Translational Data at the Alzheimer\u2019s Association International Conference 2021 (AAIC) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-to-present-ath-1017-phase-1-translational-data-at-the-alzheimers-association-international-conference-2021-aaic\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-to-present-ath-1017-phase-1-translational-data-at-the-alzheimers-association-international-conference-2021-aaic\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4MTk4MiM0MzAxNDc4IzIyMDE4OTE=\",\"datePublished\":\"2021-07-19T11:03:52+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-to-present-ath-1017-phase-1-translational-data-at-the-alzheimers-association-international-conference-2021-aaic\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-to-present-ath-1017-phase-1-translational-data-at-the-alzheimers-association-international-conference-2021-aaic\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-to-present-ath-1017-phase-1-translational-data-at-the-alzheimers-association-international-conference-2021-aaic\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4MTk4MiM0MzAxNDc4IzIyMDE4OTE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4MTk4MiM0MzAxNDc4IzIyMDE4OTE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-to-present-ath-1017-phase-1-translational-data-at-the-alzheimers-association-international-conference-2021-aaic\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Athira Pharma to Present ATH-1017 Phase 1 Translational Data at the Alzheimer\u2019s Association International Conference 2021 (AAIC)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Athira Pharma to Present ATH-1017 Phase 1 Translational Data at the Alzheimer\u2019s Association International Conference 2021 (AAIC) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-to-present-ath-1017-phase-1-translational-data-at-the-alzheimers-association-international-conference-2021-aaic\/","og_locale":"en_US","og_type":"article","og_title":"Athira Pharma to Present ATH-1017 Phase 1 Translational Data at the Alzheimer\u2019s Association International Conference 2021 (AAIC) - Market Newsdesk","og_description":"BOTHELL, Wash., July 19, 2021 (GLOBE NEWSWIRE) — Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that it will present clinical electroencephalogram (EEG) data, including in Alzheimer\u2019s patients, from the Phase 1 a\/b trial of its lead development candidate, ATH-1017, at the upcoming Alzheimer\u2019s Association International Conference 2021 (AAIC). AAIC will be held July 26-30, 2021, virtually and in Denver. Poster Presentation Details: Title: Quantitative EEG as a translational measure for the assessment of ATH-1017 neurophysiological changes in mild-to-moderate Alzheimer\u2019s disease Poster Number: 56531 Presenter: Xue Hua, Ph.D., Vice President of Clinical Development, Research, Athira Pharma Authors: Xue Hua1, Kevin Church1, William Walker1, Phillippe … Continue reading \"Athira Pharma to Present ATH-1017 Phase 1 Translational Data at the Alzheimer\u2019s Association International Conference 2021 (AAIC)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-to-present-ath-1017-phase-1-translational-data-at-the-alzheimers-association-international-conference-2021-aaic\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-19T11:03:52+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4MTk4MiM0MzAxNDc4IzIyMDE4OTE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-to-present-ath-1017-phase-1-translational-data-at-the-alzheimers-association-international-conference-2021-aaic\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-to-present-ath-1017-phase-1-translational-data-at-the-alzheimers-association-international-conference-2021-aaic\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Athira Pharma to Present ATH-1017 Phase 1 Translational Data at the Alzheimer\u2019s Association International Conference 2021 (AAIC)","datePublished":"2021-07-19T11:03:52+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-to-present-ath-1017-phase-1-translational-data-at-the-alzheimers-association-international-conference-2021-aaic\/"},"wordCount":901,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-to-present-ath-1017-phase-1-translational-data-at-the-alzheimers-association-international-conference-2021-aaic\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4MTk4MiM0MzAxNDc4IzIyMDE4OTE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-to-present-ath-1017-phase-1-translational-data-at-the-alzheimers-association-international-conference-2021-aaic\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-to-present-ath-1017-phase-1-translational-data-at-the-alzheimers-association-international-conference-2021-aaic\/","name":"Athira Pharma to Present ATH-1017 Phase 1 Translational Data at the Alzheimer\u2019s Association International Conference 2021 (AAIC) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-to-present-ath-1017-phase-1-translational-data-at-the-alzheimers-association-international-conference-2021-aaic\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-to-present-ath-1017-phase-1-translational-data-at-the-alzheimers-association-international-conference-2021-aaic\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4MTk4MiM0MzAxNDc4IzIyMDE4OTE=","datePublished":"2021-07-19T11:03:52+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-to-present-ath-1017-phase-1-translational-data-at-the-alzheimers-association-international-conference-2021-aaic\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-to-present-ath-1017-phase-1-translational-data-at-the-alzheimers-association-international-conference-2021-aaic\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-to-present-ath-1017-phase-1-translational-data-at-the-alzheimers-association-international-conference-2021-aaic\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4MTk4MiM0MzAxNDc4IzIyMDE4OTE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4MTk4MiM0MzAxNDc4IzIyMDE4OTE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-to-present-ath-1017-phase-1-translational-data-at-the-alzheimers-association-international-conference-2021-aaic\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Athira Pharma to Present ATH-1017 Phase 1 Translational Data at the Alzheimer\u2019s Association International Conference 2021 (AAIC)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/514331","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=514331"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/514331\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=514331"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=514331"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=514331"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}